Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • br Introduction Few decades after of

    2021-10-26


    Introduction Few decades after of HIV/AIDS diagnosis, it has been still a health problem and impact will continue in the next decades. In 2015, HIV/AIDS was the 12th cause of death in the world and it's estimated that 1.2 million people was died of HIV/AIDS this year. In the global epidemiological study of AIDS in 2014, the overall prevalence of this disease was reported to be 0.05% in individuals aged 15–49 years and the highest frequency of HIV/AIDS has been reported in Sub-Saharan Africa and then in Asia. Considering the progression of HIV/AIDS and the disability and mortality that followed the disease, it was tried to produced different drug against it and there has been a remarkable development in this field. Among with main antiviral drugs, there has been some efforts in auxiliary drugs effects, but these findings are not adequate and studies are not enough. One of these drugs is Coenzyme Q10 (CoQ10). Naturally, this enzyme there is in the body. The function of this coenzyme as a cofactor is in the po1 transmission chain in mitochondria that acts in the synthesis of adenosine triphosphate (ATP). In addition, it increases the activity of macrophages, as well as the proliferation of granulocytes. CoQ10 also works an intracellular antioxidant at the mitochondrial surface. So, theoretically, it seems that this drug is useful in patients with HIV due to increased proliferation of granulocytes and it prevents cardiomyopathy and oxidative stress induced lipidostrophy by antioxidant activity.,
    Material and methods This randomized, double blind, placebo controlled, parallel group clinical trial was performed on 73 patients with human immunodeficiency virus infected. This study registered in the clinical trial registry with code IRCT201108027197N1. The studied population was HIV-infected adults that HIV confirmed with 2 positive results of ELISA and western blot test and they are in treatment with ART. The sample size according to the pilot study in 10 people at 95% confidence level and 80% power were obtained 37 patients in each group by two sample comparison of means formula. Exclusion criteria included: immunodeficiency diseases for other causes, including lymphoma or other malignancies, Use of drugs that affect the immune system, such as corticosteroids, autoimmune diseases, advanced pulmonary tuberculosis and pregnant women. In these patients, the baseline level of CD4 was measured with flowcytometry. The levels of liver enzymes, BUN, Cr, and CBC were also measured and recorded. Patients selected with convenience method and then randomly assigned to two groups with using random table and the drug or placebo was received by a third person (nurse) without the information. One group received CoQ10, 200 mg daily and the other group received placebo, were completely consistent with CoQ10 in terms of shape, color, and size. After 3 months, the above parameters are measured again and were compared in two groups. The initial outcome was change in the rate of CD4 and the secondary outcome was change in the values of ALKP, ALT, AST, BUN, creatinine, white blood cells, hemoglobin and platelets. Data were analyzed by SPSS19 and statical test such as t-test, paired t-test and chi-square test and the per-protocol method was used in the therapeutic effect analysis and p < 0.05 was considered as a significant level. Normality was checked by histogram.
    Results Finally, 37 patients in the intervention group and 36 patients in the placebo group were studied. There was only one loss to follow up case in the placebo group. The distribution of the demographic parameters of the subjects in intervention and placebo groups are shown in Table 1. The mean age of the patients in the intervention and placebo groups was 39 ± 10 and 41 ± 10, respectively (p = 0.423). In the intervention group, 83.8% and in the placebo group, 69.4% were male (p = 0.175). There was no significant difference between addiction and hepatitis B and C in both groups (P > 0.05).